Ofloxacin is a synthetic carboxyquinolone antimicrobial agent which exhibits broad-spectrum in vitro bactericidal activities against gram-positive and gram-negative aerobes (5) . The clinical efficacy of ofloxacin has been documented in patients with respiratory tract, upper and lower urinary tract, and skin and soft tissue infections and gonococcal and nongonococcal urethritis (5, 8) . In December 1990, the oral tablet formulation of ofloxacin was approved by the U.S. Food and Drug Administration, and marketing commenced in February 1991.
In certain circumstances, such as in patients who are seriously ill, have ileus, or are nauseated and/or vomiting, the oral route of ofloxacin administration may not be appropriate. In these situations, an intravenous (i.v.) formulation may prove useful. This study was designed to evaluate the safety and pharmacokinetics of multiple-dose intravenous (i.v.) ofloxacin in healthy adult volunteers in two proposed therapeutic dosing regimens (200 and 400 mg every 12 h
[ql2h]).
MATERIALS AND METHODS
Volunteers. Healthy male volunteers, aged 18 to 40 years inclusive, participated in the study after granting written, informed consent as approved by the Human Subjects Review Committee of Hennepin County Medical Center and the Institutional Review Board of the Clinical Research Center, Tulane University School of Medicine. Subjects were judged to be healthy on the basis of normal findings on medical history, physical and neurological examinations, clinical laboratory tests, electroencephalography, and electrocardiography.
Design. This study was conducted as a two-center, doubleblind, randomized placebo-controlled, parallel study, with the protocols of 200 and 400 mg ql2h conducted at the University of Minnesota and Tulane University, respectively. Subjects were randomized to receive either 200 or 400 mg of ofloxacin or identical placebo ql2h as 1-h i.v. infusions for 7 days. Subjects were confined from 12 h prior to administration of the first dose until after all final plasma and urine samples had been collected. Ingestion of caffeine and alcohol was prohibited during the study period.
The safety tests that were performed included audiometry, ophthalmology (funduscopy, slit lamp, tonometry, color vision, acuity), clinical laboratory tests, electrocardiography (performed prestudy and on days 1, 4, and 8), and electroencephalography (performed prestudy and on days 2 and 5). In addition, urine was screened for crystalluria daily during treatment, and visual reaction times (assessed by using a brake reaction timer [American Automobile Association, Heathrow, Fla.]) were obtained prestudy and on days 1 and 4 of treatment.
Blood samples of 5 ml were obtained from the arm contralateral to the infusion site immediately prior to the morning doses on days 1 through 7. In addition, blood samples were obtained on days 1, 4, and 7 at 0.5 h after the start of the morning infusion; at the end of the infusion; and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 11 h after the end of the infusion. Blood samples were also obtained 24, 36, 48, and 60 h after the start of the final infusion. Blood samples were collected in heparinized tubes and centrifuged, and the plasma was separated and stored frozen at -20°C until it was assayed.
Specimen analysis. The concentration of ofloxacin in plasma was determined by a high-pressure liquid chromatography method. After extraction at pH 7 with dichloromethane, the extract was injected onto a C18 ,uBondapak column (25 cm by 4 of methanol and adjusted to pH 3 with phosphoric acid. An imidazolic analog of ofloxacin (Daiichi Seiyaku) was used as the internal standard. Detection at 313 nm was done with a UV detector. The limit of quantitation was 0.01 mg/liter, and the extraction efficiency was greater than 95%. The assay was linear over the concentration range of 0.025 to 9 mg/liter. The intra-and interday coefficients of variation ranged from 3 to 6% over the standard curve concentration range of 0.025 to 9 mg/liter (2). Pharmacokinetic analysis. Pharmacokinetic analysis was done as described previously (3). Areas under the plasma concentration-versus-time curve from time zero to 12 h (AUCO_12) on days 1, 4, and 7 and from time zero to 60 h (AUCO w) on day 7 were determined by trapezoidal integration. The elimination rate constant (kel) and terminal disposition half-life (t1/2,) were determined from model fitting of the 0-to 12-h postdose plasma concentration-versus-time data to polyexponential equations by using CSTRIP (7) followed by nonlinear regression analysis using PC NON-LIN (Statistical Consultants, Lexington, Ky.). Data fits were unweighted, and the appropriate exponential model was determined by examining the Akaike information criterion (1, 9), the sum of weighted residuals, and the observed versus fitted plasma concentration-versus-time data. Each subjects' day 1, 4, and 7 data fits were analyzed independently. Plasma clearance (CL) was calculated by dividing the dose by AUCO, 12 on days 4 and 7. The apparent volume of distribution (V) was calculated by dividing CL by k,1.
Statistical analysis. Analysis of variance followed by the Tukey-Kramer test was performed to determine whether significant differences occurred between days for the AUC, keI, CL, and V parameters. Bartlett's test was used to determine the homogeneity of variance between days for the AUC, morning trough concentrations (Cmin), kel, CL, and V parameters. Friedman's test with Page's statistic and Doksum's test with Hollander's statistic were performed to test for day-to-day differences and trends on the ranked Cmin values. Comparisons between the ofloxacin and placebo groups regarding adverse experiences were determined by using a one-tailed Fisher's exact test. Adverse experience rates were calculated as the number of subjects with a given experience divided by the total number of subjects that were evaluable for safety. All statistical evaluations were performed by using the SAS statistical package (6) . Significance was assessed at the 5% level. Data are presented as means ± standard deviations unless otherwise noted.
RESULTS
Patient demographics. Demographics of the groups receiving 200 mg of ofloxacin and placebo at the University of Minnesota and the groups receiving 400 mg of ofloxacin and placebo at Tulane University are given in Table 1 . Withinand between-site comparisons of the ofloxacin and placebo groups from both study sites did not reveal any statistically significant differences in demographic parameters.
Safety. At the University of Minnesota site, two ofloxacin recipients were switched to placebo in a blinded fashion because of adverse events. One of these subjects developed a fine macular erythematous rash on his back and front torso during the morning dose on study day 4; the rash resolved spontaneously after the switch to placebo. The other subject developed dizziness and tachycardia as well as erythema and pruritus at the i.v. infusion site during the initial infusion; these adverse events also resolved spontaneously after the switch to placebo. All recipients of 200 mg of placebo completed the study. Overall, 8 of 12 subjects who received 200 mg of ofloxacin and 8 of 12 subjects who received placebo experienced adverse events during the study. A total of 49 and 32 adverse events were reported in the ofloxacin and placebo recipients, respectively. These were the totals of all reactions independent of the degree of association to study therapy. Adverse events (number of subjects in parentheses) in the ofloxacin group included extremity pain (n = 1), dizziness (n = 1), headache (n = 2), paresthesia (n = 1), ocular dryness (n = 1), ocular redness (n = 1), edema (n = 1), tachycardia (n = 1), abnormal chest sounds (n = 1), diarrhea (n = 5), urinary incontinence (n = 1), skin erythema (n = 2), rash (n = 1), and i.v. infusion site skin reaction (n = 30). Adverse events in the placebo group included chills (n = 1), trunk pain (n = 1), extremity pain (n = 2), headache (n = 1), syncope (n = 1), edema (n = 2), gastrointestinal cramps (n = 2), gastrointestinal distress (n = 1), diarrhea (n = 3), skin lesions (n = 1), skin erythema (n = 3), and i.v. infusion site skin reaction (n = 14). There were no statistically significant differences between the ofloxacin and placebo groups in terms of vital signs at baseline or mean changes. No subjects in either group developed neurological abnormalities during the study. No clinically significant alterations in ophthalmologic, audiometric, electrocardiographic, electroencephalographic, or clinical laboratory tests were noted in either group over the course of the study. In addition, there were no statistically significant within-group or between-group differences in visual reaction times (data not shown).
At the Tulane University site, all 24 enrolled subjects (12 who received ofloxacin, 12 who received placebo) completed participation in the study. Overall, 5 of 12 subjects who received 400 mg of ofloxacin and 3 of 12 subjects who received placebo experienced adverse events during the study. A total of 16 and 8 events were reported in the ofloxacin and placebo recipients, respectively. As stated above, these totals were independent of the degree of association to study therapy. Adverse events in the ofloxacin group included dizziness (n = 1), headache (n = 1), otalgia (n = 1), vasodilation (n = 2), pharyngitis (n = 1), constipation (n = 1), keratoderma (n = 1), rash (n = 1), i.v. infusion site skin reaction (n = 5), diaphoresis (n = 1), and muscle stiffness (n = 1). Adverse events in the placebo group included dizziness (n = 1), tremor (n = 1), dream abnormality (n = 1), dyspnea (n = 1), pharyngitis (n = 1), rash (n = 2), and arthralgia (n = 1). As in the University of Minnesota subjects, there were no statistically or clinically significant alterations in ophthalmologic, audiometric, electrocardiographic, electroencephalographic, clinical laboratory, or visual reaction time tests in either study group.
The discrepancies in i.v. infusion site skin reaction rates between the two study sites may have been due to the racial imbalance in study populations between the study sites. At the University of Minnesota site, the major i.v. infusion site skin reaction in both study groups was erythema (15 of 30 reactions in ofloxacin recipients, 11 of 14 reactions in placebo recipients), which occurred in a predominantly Caucasian study population. Perhaps the predominance of blacks at the Tulane University site made assessment of erythema as a reaction more difficult, leading to the much lower i.v. infusion site reaction incidence noted at that site.
Pharmacokinetics. The mean plasma concentration-versus-time curves for the 200-and 400-mg ql2h multiple-dose groups are illustrated in Fig. 1 and 2 , respectively. The pharmacokinetic parameters for both dosing groups are given in Table 2 . Ofloxacin plasma concentration-versustime data were best fit by a two-compartment open model in all subjects. The harmonic mean t1/2 for days 1, 4, and 7 for the 200-mg group (4.28, 4.91, and 4.98 h, respectively) and 400-mg group (5.06, 6.00, and 6.67 h, respectively) were comparable intradose and interdose (P was not significant for all comparisons). Comparable results were obtained when examining intradose and interdose CL and V data. Steady state was achieved by day 2 in both dosing groups, as evidenced by the nonsignificant differences in Cmin from study days 2 to 7 (Fig. 3) . Intradose comparisons of AUCO12 data in both the 200-mg (AUCO, 12 day 4 = 12.96 ± 1.62 mg * h/liter versus AUCO_12 day 7 = 12.71 + 1.34 mg. h/ liter; P was not significant) and 400-mg (AUCO_12 day 4 = 30.17 ± 6.26 mg. h/liter versus AUCO12 day 7 = 28.99 + 6.98 mg-h/liter; P was not significant) groups corroborated the results of the Cmin data analysis. Interdose comparisons of the AUCO_12 on days 1, 4, and 7 and the AUCO-60 on day 7 revealed that the values for the recipients of 400 mg were not statistically significantly different from double the respective values for the recipients of 200 mg. Statistical analysis revealed no significant race-related differences in AUC, t1/2., CL, or V, even when logistic regression was used to examine the dose-race interaction. 
